PharVision Advisers’s Aimco AIV Stock Holding History

PharVision Advisers’s Portfolio AIV Stock Details AIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-45,442	Closed	-$270K	–	113
2025 Q4	$270K	Buy	+45,442	New	+$272K	0.14%	341

Other funds holding AIV

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

PharVision Advisers's AIV Position: Q1 2026 in Review

PharVision Advisers sold out of Aimco (AIV) in Q1 2026, closing a stake of 45,442 shares — an estimated $270K sold.

PharVision Advisers first reported a position in AIV in Q4 2025 and held it in 1 quarter. The position peaked at $270K in Q4 2025. 187 funds tracked by Wall St. Rank hold AIV as of Q1 2026.

PharVision Advisers reported no remaining Aimco position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 45,442 Aimco shares in Q1 2026, an estimated $270K.
PharVision Advisers first reported a position in Aimco in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Aimco position peaked at $270K in Q4 2025.
187 funds tracked by Wall St. Rank held Aimco as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.